Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma
Kazutaka Nakamura, Kazuhiko Yoshida, Yuki Kobari, Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hiroaki Shimmura, Hiroshi Kobayashi, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi · 2026
Read Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma by Kazutaka Nakamura, Kazuhiko Yoshida, Yuki Kobari, Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hiroaki Shimmura, Hiroshi Kobayashi, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585830.txt.
Description
Kazutaka Nakamura and eleven co-authors compare two drug pairs for spread kidney cancer in a 2026 paper. The pairs join a targeted drug with an immune drug. One pair is cabozantinib plus nivolumab. The other is lenvatinib plus pembrolizumab. Both are used as first treatment for metastatic renal cell carcinoma.
The study looked back at 92 patients treated at several centers. Time without growth and total survival did not differ clearly between the pairs. The first pair shrank tumors in more patients, at 79 percent against 49 percent. Disease control and severe side effects were much the same. A risk score, not the drug pair, best foretold time without growth. The authors say both pairs are valid first choices.
Catalog record
| CREATOR | Kazutaka Nakamura, Kazuhiko Yoshida, Yuki Kobari, Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hiroaki Shimmura, Hiroshi Kobayashi, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |